Is TransMedics Group, Inc. overvalued or undervalued?

As of 7 November 2025, the valuation grade for TransMedics Group, Inc. moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a P/E ratio of 96, a Price to Book Value of 17.67, and an EV to EBITDA of 66.22, which suggest that while the stock is not undervalued, it is also not excessively priced compared to its recent valuation history.
In comparison to its peers, TransMedics has a significantly higher P/E ratio than CONMED Corp., which stands at 19.96, and a lower EV to EBITDA than Integer Holdings Corp. at 41.17. This indicates that while TransMedics may be on the higher end of the valuation spectrum, it still holds a competitive position within its industry. Notably, the stock has outperformed the S&P 500 with a year-to-date return of 96.30% compared to the S&P 500's 14.40%, reinforcing the notion that the market recognizes its growth potential.